Prescription medication · Echinocandin Antifungal
anidulafungin
Also sold as Eraxis. Eraxis treats candidemia and other Candida infections, like intra-abdominal abscesses and peritonitis.
Data updated 2026-05-15
- 1,527
- FDA reportsRarely reported
- 4
- InteractionsFew interactions
- Rx
- Availability
What the data shows
anidulafungin (Eraxis) is a prescription Echinocandin Antifungal, among the least-reported drugs the FDA tracks (1,527 FDA reports), with 4 documented drug interactions.
Reporting volume reflects how widely a drug is used and studied, not how dangerous it is, a FAERS report documents a temporal association, never proof of cause.
anidulafungin (Eraxis) is a prescription Echinocandin Antifungal. Eraxis treats candidemia and other Candida infections, like intra-abdominal abscesses and peritonitis.
Eraxis is an antifungal medicine. It treats certain Candida infections in your body.
Verify with FDA → · CMS NADAC pricing →
What it does
Eraxis treats candidemia and other Candida infections, like intra-abdominal abscesses and peritonitis.
Common side effects
Low potassium levels, Nausea, Diarrhea
Key warnings
Eraxis can cause liver problems.
The sections below are summarized in plain English from anidulafungin's FDA-approved prescribing information. They describe what the official label says, and are not personal medical advice.
How It Works
Eraxis belongs to a class of drugs called echinocandins. It works by stopping the growth of the fungus Candida. It does this by blocking a key part of the fungal cell wall.
Side Effects (from patient reports)
Based on 1,527 FDA adverse event reports.
Most-reported reactions
Adverse reactions in FAERS for anidulafungin, by number of reports
- Multiple Organ Dysfunction Syndrome
Multiple Organ Dysfunction Syndrome
171 reports
- Septic Shock
Septic Shock
127 reports
- Sepsis
Sepsis
115 reports
- Pneumonia
Pneumonia
94 reports
- Pyrexia
Pyrexia
90 reports
- Candida Infection
Candida Infection
89 reports
- Death
Death
81 reports
- Neutropenia
Neutropenia
78 reports
- Renal Failure 68
Renal Failure
68 reports
- Respiratory Failure 63
Respiratory Failure
63 reports
What this shows Bars show how often each reaction was reported, not how likely it is to happen, a report records a temporal association, never proof that the drug caused it.
Reports over time
Adverse-event reports filed for anidulafungin each year to the FDA Adverse Event Reporting System (FAERS).
Year-to-year volume tracks usage, prescribing, and scrutiny, not a change in per-patient risk. Source: FDA FAERS.
Where anidulafungin sits
anidulafungin has more FDA adverse-event reports than 10% of the drugs FAERS tracks. A high position reflects how widely a drug is used and watched, not how dangerous it is.
Percentile across all drugs PlainMeds tracks by FAERS report volume. The dot is anidulafungin; the line is the median (50th percentile).
FDA Adverse Event Report Analysis
Detailed analysis of 1,527 reports from the FDA Adverse Event Reporting System (FAERS). Reports span 2006–2025.
Total Reports
1,527
Reports Mentioning Death
665
43.5% of reports — not proof of cause
Hospitalization Reports
741
Top Indication
Product Used For Unknown Indication
Gender Distribution
Age Distribution
Most Reported Adverse Reactions (FAERS)
| # | Reaction | Reports |
|---|---|---|
| 2 | MULTIPLE ORGAN DYSFUNCTION SYNDROME | 171 |
| 4 | SEPTIC SHOCK | 127 |
| 5 | SEPSIS | 115 |
| 6 | PNEUMONIA | 94 |
| 7 | PYREXIA | 90 |
| 8 | CANDIDA INFECTION | 89 |
| 9 | DEATH | 81 |
| 10 | NEUTROPENIA | 78 |
| 11 | RENAL FAILURE | 68 |
| 12 | RESPIRATORY FAILURE | 63 |
| 13 | CONDITION AGGRAVATED | 59 |
| 14 | DRUG RESISTANCE | 58 |
| 15 | HYPOTENSION | 57 |
| 16 | ACUTE KIDNEY INJURY | 56 |
| 17 | THROMBOCYTOPENIA | 56 |
Reactions in Death Reports
Reactions in Hospitalization Reports
Source: FDA FAERS (Adverse Event Reporting System) Reports are voluntary and do not establish causation
Serious Warnings
Eraxis can cause liver problems. Your doctor should check your liver function while you are taking Eraxis. Allergic reactions, including shock, can happen. Tell your doctor right away if you have any signs of an allergic reaction, like rash, hives, flushing, itching, trouble breathing, or low blood pressure. Eraxis contains fructose. If you have hereditary fructose intolerance, you should not take Eraxis.
Known Drug Interactions
7 DRUG INTERACTIONS 7.1 Cyclosporine Administration of multiple doses of anidulafungin and cyclosporine to healthy subjects resulted in no significant alteration in the steady state pharmacokinetics of either drug. No dosage adjustment of cyclosporine or anidulafungin is needed when the two drugs are co-administered [see Clinical Pharmacology (12.3) ] .
Mechanism: These two drugs do not change how the body processes or breaks down each other. They can be used together without affecting the amount of medicine in your blood.
7.4 Rifampin Administration of multiple doses of anidulafungin and rifampin to patients resulted in no significant alteration in the steady state pharmacokinetics of anidulafungin. No dosage adjustment of anidulafungin is needed when it is co-administered with rifampin [see Clinical Pharmacology (12.3) ] .
Mechanism: Taking these medicines together does not change the level of either drug in your system. They do not interfere with how the body handles the medication.
7.2 Voriconazole Administration of multiple doses of anidulafungin and voriconazole to healthy subjects resulted in no significant alteration in the steady state pharmacokinetics of either drug. No dosage adjustment of voriconazole or anidulafungin is needed when the two drugs are co-administered [see Clinical Pharmacology (12.3) ] .
Mechanism: These drugs do not affect how the body uses or removes either medication. Their levels in the blood stay the same when they are taken together.
7.5 Amphotericin B Liposome for Injection Administration of multiple doses of anidulafungin and liposomal amphotericin B to patients resulted in no significant alteration in the steady state pharmacokinetics of anidulafungin. No dosage adjustment of anidulafungin is needed when it is co-administered with liposomal amphotericin B [see Clinical Pharmacology (12.3) ] .
Mechanism: These medications do not interfere with each other's levels in the body. They do not change how the body processes the medicine.
This is a plain-language summary of FDA-label interaction records and does not provide individual medication-combination directions.
Common Questions
How long will I need to take Eraxis?
Can Eraxis be given to children?
What should I tell my doctor before taking Eraxis?
Can I take other medicines with Eraxis?
What is a loading dose?
How will Eraxis be given to me?
What if I have side effects from Eraxis?
Can Eraxis cure my infection?
What does 'not approved' mean for Esophageal candidiasis in children?
What is Candida?
What are the common side effects of anidulafungin?
Does anidulafungin interact with other medications?
What drug class is anidulafungin?
What pregnancy or breastfeeding source fields are listed for anidulafungin?
Related Medications in Echinocandin Antifungal
Other drugs grouped near anidulafungin - same-class peers and common alternatives.
acyclovir
Zovirax
Acyclovir is an antiviral medicine.
Compare with anidulafungin →
albendazole
Albenza
Albendazole is a medicine that fights parasites.
Compare with anidulafungin →
amphotericin B
Ambisome, Fungizone
Amphotericin B liposome is an antifungal medicine.
Compare with anidulafungin →
atovaquone/proguanil
Malarone
Malarone is a drug used to prevent and treat malaria.
Compare with anidulafungin →
baloxavir marboxil
Xofluza
Xofluza is an antiviral medicine that can treat the flu.
Compare with anidulafungin →
Compare beyond drug class
Nationwide peers by FAERS volume & death-report share
Two PlainMeds-derived comparison paths for anidulafungin: nearest FDA FAERS report volume and nearest death-report share among drugs with at least 1,000 logged reports, excluding same-class neighbors listed above. Counts reflect reporting volume, not proven individual harm.
Similar FAERS report volume
Nearest drugs by total FAERS reports. This record: 1,527.
Similar death-report share
Nearest drugs by FAERS death-report share. This record: 43.55%.
- phenylephrine Δ 1.60 pts · 3,669 reports · Alpha-1 Agonist 41.95%death share
- vasopressin Δ 4.06 pts · 4,135 reports · Vasopressin Receptor Agonist 39.49%death share
- dobutamine Δ 5.25 pts · 3,554 reports · Inotropic Agent (Beta-1 Agonist) 38.29%death share
- amphotericin B Δ 6.96 pts · 17,512 reports · Polyene Antifungal 36.59%death share
Medication Guides
Understanding Drug Interactions
How CYP450 enzymes, inhibitors, and inducers affect your medications
Generic vs Brand Name Drugs
FDA requirements, cost savings, and when the difference matters
Narrow Therapeutic Index Drugs
FDA bioequivalence and label-record context for narrow therapeutic index medicines
Common Drug Interactions
Dangerous medication combinations and how to protect yourself
Save on anidulafungin
Compare prices and find discounts at pharmacies near you. Free coupons can save up to 80% on prescriptions.
Disclosure: This link may earn us a commission at no extra cost to you. See our terms.
What the FDA Data Shows for anidulafungin
The FDA label for anidulafungin (sold under brand names such as Eraxis) classifies it as a prescription-only medication in the Echinocandin Antifungal class. Eraxis treats candidemia and other Candida infections, like intra-abdominal abscesses and peritonitis. Official labeling lists 17 commonly reported side effects, including Low potassium levels, Nausea, Diarrhea.
Post-market surveillance from the FDA Adverse Event Reporting System (FAERS) captures real-world experience. For this drug, FAERS contains 1,527 voluntary reports. The database also lists 4 documented drug interactions derived from FDA labeling, with the top-flagged interaction rated minor severity. Acquisition-cost data is surveyed weekly by CMS and updated as manufacturers report changes.
Report counts do not establish causation, a FAERS entry documents a temporal association, not proof that the drug produced the outcome. Widely prescribed medications naturally accumulate more reports than niche therapies, so raw totals must be interpreted alongside total exposure. Shortage status, recall history, and patent information are separate source-record fields. This page is a public FDA/CMS registry and does not provide medical, treatment, substitution, or medication-change directions.
Data Sources
Drug labeling: FDA Drug Labels (SPL/DailyMed). Adverse events: FDA Adverse Event Reporting System (FAERS).
FAERS reports are voluntary and do not establish causation. Drug interactions are derived from FDA labeling and clinical references. This registry does not provide medication decisions.
Last updated: August 19, 2025
PlainMeds is rendered directly from FDA openFDA/FAERS extracts, DailyMed labels, and CMS drug-pricing files, no number is typed in by an editor. FAERS counts, recalls, shortages, and price figures on this page are queried live from those federal extracts. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error. Data current as of 2026-05-15. Primary sources: openFDA / FAERS, DailyMed and CMS Part B ASP.
Read our methodology - how this data is sourced, computed, and verified.
Data currency: FDA FAERS adverse-event reports through 2025, CMS NADAC acquisition-cost pricing effective December 2024, compiled from the source snapshot dated . See our methodology for per-source dates and refresh cadence. Spot a figure that looks wrong? Report a data issue.
All federal data sources used on this page
- FDA Orange Book - approved drug products with therapeutic equivalence. accessdata.fda.gov/cder/ob
- FDA DailyMed - NIH-hosted drug labeling for FDA-approved meds. dailymed.nlm.nih.gov
- FDA Adverse Event Reporting System (FAERS) - post-marketing safety surveillance. fda.gov/drugs/faers
- NLM RxNorm - standardized clinical drug nomenclature. nlm.nih.gov/research/umls/rxnorm
- CMS Medicare Part B Drug Average Sales Price Files - federal drug pricing data. cms.gov/medicare/part-b-drugs/asp
- FDA Drug Shortages Database - current and resolved drug shortage tracking. accessdata.fda.gov/drugshortages